2pcs Tail K100 XK V966 V911S WLtoys for Complete Assembly,Motor/Boom/Motor Other RC Parts & Accs


  1. Home
  2. 2pcs Tail K100 XK V966 V911S WLtoys for Complete Assembly,Motor/Boom/Motor
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
2pcs Tail Assembly,Motor/Boom/Motor Complete for WLtoys V911S V966 XK K100
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Brand:

Unbranded

Compatible Brand: WLtoys V911S V966 XK K100 Type: Parts
Size: 14.4cm MPN:

Does Not Apply

Country/Region of Manufacture: China Colour: Black
Quantity: 4 UPC:

Does not apply

ISBN:

Does not apply

EAN:

Does not apply













published on tue nov 09 2021

2pcs Tail K100 XK V966 V911S WLtoys for Complete Assembly,Motor/Boom/Motor Other RC Parts & Accs

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

2pcs Tail K100 XK V966 V911S WLtoys for Complete Assembly,Motor/Boom/Motor Other RC Parts & Accs

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS